Previous 10 | Next 10 |
Mechelen, Belgium ; 17 September 2021 ; 13.15 CET ; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opi...
Galapagos NV (NASDAQ:GLPG) announces the planned retirement of CEO Onno van de Stolpe. Onno van de Stolpe co-founded Galapagos in 1999 and built and led the company as CEO from its early R&D days through to the commercial launch of Jyseleca in Europe. “My t...
Mechelen, Belgium; 30 August 2021, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces the planned retirement of CEO Onno van de Stolpe. Onno van de Stolpe co-founded Galapagos in 1999 and built and led the company as CEO from its ear...
Galapagos NV (GLPG) Q2 2021 Earnings Conference Call August 6, 2021 08:00 AM ET Company Participants Sofie Van Gijsel - IR Onno van de Stolpe - CEO Dr. Walid Abi-Saab - CMO Bart Filius - COO and President Conference Call Participants Brian Abrahams - RBC Capital Markets Laura Sutcliffe - UBS ...
Image source: The Motley Fool. Galapagos NV (NASDAQ: GLPG) Q2 2021 Earnings Call Aug 6, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Galapagos NV (GLPG) Q2 2021 Earnings Call Transcript
First half-year 202 1 financial results : Group revenues and other income of € 277.2 million Operating loss of € 97.6 million Net loss of € 55.0 million Cash and c ...
Shares of Galapagos (NASDAQ: GLPG) , a biopharmaceutical company, are under pressure following clinical trial readouts for a couple of new drug candidates in phase 1 studies. Disappointing results from the company's Toledo program pushed the stock 13.1% lower as of 3:52 p.m. EDT on ...
Mikhail Leonov/iStock via Getty Images Earnings reports remain the biggest headline-grabbers on Thursday. This included a couple of big names that dipped following the release of their quarterly results. Both Taiwan Semiconductor (TSM) and Morgan Stanley (MS) lost ground before the bell on ea...
coffeekai/iStock via Getty Images Galapagos (GLPG) has lost ~11.3% in the pre-market after the company announced underwhelming data for oral SIK inhibitor GLPG3970 in a Phase 2a trial for rheumatoid arthritis ((RA)). However, the experimental therapy showed a positive effect after s...
IMV IMV -20% on $25M capital raiseGalapagos GLPG -12% topline results from early-stage GLPG3667 psoriasis studyPop Culture (CPOP) -8%.Yunhong CTI (CTIB) -7%.Tempest Therapeutics (TPST) -7%.U.S. Energy (USEG) -7%.Exela Technologies (XELA) -6%.Oxbridge Re Holdings (OXBR) -6%...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...